AKT1 and lung cancer: Interestingly, according to the results of this study, we found the gefitinib failed to suppress the activation of PI3K/AKT pathway in the lung cancer stem cells in vitro and in vivo, whereas the EGFR signaling could be inhibited by this kind of EGFR-TKI.